Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY, Ferronha T, Sanderson JP, Weissensteiner T, Pope GR, Bennett AD, Pumphrey NJ, Ferjentsik Z, Quinn LL, Wiedermann GE, Anderson VE, Saini M, Maroto M, Norry E, Gerry AB.
Docta RY, et al. Among authors: ferjentsik z.
Hepatology. 2019 May;69(5):2061-2075. doi: 10.1002/hep.30477. Epub 2019 Feb 14.
Hepatology. 2019.
PMID: 30561769
Free PMC article.